Posters Overview
The Cytochrome P450 (CYP) families of enzymes are commonly involved in significant clinical drug-drug interactions (DDIs). A change in the metabolic clearance of these drugs due to changes in the CYP activities can produce severe adverse reactions or a loss of efficacy when two or more drugs are co-administered. To avoid failures in the later stages of drug development or post-marketing, an evaluation of the effects of new molecular entities (NMEs) on CYP activities during the early stages of drug discovery is crucial.
Complete the form to view and download this poster.
Stay Connected
Keep up with the latest news and insights.